The Lung Cancer Research Foundation is pleased to announce this year’s requests for proposals (RFPs) for the LCRF-AstraZeneca Grant Program, LCRF Pilot Grant Program and LCRF Research Grant on Disparities in Lung Cancer.

  • The LCRF-AstraZeneca Grant Program supports research that will help to address the most profound challenges posed by targeted therapies and immune therapies in lung cancer.

    As LCRF’s newest funding mechanism available to lung cancer researchers, the LCRF-AstraZeneca Grant Program was announced on February 23, 2021. Its objective is understanding primary and acquired resistance to targeted therapies, and the biology surrounding that resistance. View the RFP here. Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2021.
  • The LCRF Pilot Grant Program supports innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, and other research, on a very broad variety of topics related to lung cancer. View the RFP here. Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2021.
  • The LCRF Research Grant on Disparities in Lung Cancer supports research projects focused on a wide variety of disparities-related topics in lung cancer from investigators of all career levels. While scientific advances continue to reduce lung cancer incidence and deaths, the disease disproportionately affects various groups such as African Americans, Native Americans, low socioeconomic status populations, and people from certain geographic locations. Despite progress to reduce the burden of tobacco, disparities in tobacco-related morbidity and mortality remain, and inequitable receipt of evidence-based lung cancer care continues to compound these disparities.[1][2][3][4] RFP applications will be accepted through May 7, 2021.

Please note that applicants may only apply for one LCRF grant per grant cycle. Eligibility requirements and instructions for application are included in the RFP documents linked in each of the funding mechanism’s description.

[1] American Cancer Society. Cancer Facts & Figures for African Americans 2019-2021. Atlanta: American Cancer Society; 2020.

[2] Bach, P. B., L. D. Cramer, J. L. Warren, and C. B. Begg. “Racial Differences in the Treatment of Early-Stage Lung Cancer.” The New England Journal of Medicine 341, no. 16 (October 14, 1999): 1198–1205.

[3] Corso, Christopher D., Henry S. Park, Anthony W. Kim, James B. Yu, Zain Husain, and Roy H. Decker. “Racial Disparities in the Use of SBRT for Treating Early-Stage Lung Cancer.” Lung Cancer (Amsterdam, Netherlands) 89, no. 2 (August 2015): 133–38.

[4] Yang, Relin, Michael C. Cheung, Margaret M. Byrne, Youjie Huang, Dao Nguyen, Brian E. Lally, and Leonidas G. Koniaris. “Do Racial or Socioeconomic Disparities Exist in Lung Cancer Treatment?” Cancer 116, no. 10 (May 15, 2010): 2437–47.